New local NHS models help to deliver integrated care
October 31, 2018 |
Steve How, of Wilmington Healthcare, explains how health and social care groups are uniting within ‘neighbourhoods’
Introduction
GP practices have been joining forces to create integrated units that can each serve a patient population of around 30,000-50,000 – about the same reach as a large supermarket and the agreed optimal size for Accountable Care Organisations internationally.
These integrated units are designed to enable staff from local community, mental health and acute trusts, social care and the voluntary sector to unite, and work together alongside GPs in order to provide joined up care closer to patients’ homes and reduce hospital admissions.
Known as “neighbourhoods” of care these units have become the local delivery vehicles for Sustainability and Transformation Partnerships (STPs) and Integrated Care Systems (ICSs).
Neighbourhoods of Care
There have been various routes to achieving neighbourhoods so far, with GP practices uniting to form hubs, local integrated care partnerships, federations, super-surgeries and NAPC’s primary care homes.
Neighbourhoods are beginning to take services out of hospitals and into the community for conditions, such as diabetes, musculoskeletal (MSK) disorders and mental health, and their multi-agency membership is key to achieving this goal.
The NHS is also encouraging inter-practice referrals within these neighbourhoods and enabling the creation of ‘super health centres’ within neighbourhoods that specialise in particular therapy areas, such as diabetes, in order to provide care more effectively within the community.
Furthermore, these neighbourhoods allow multidisciplinary teams from different organisations to work together. Consequently, mental health teams, district nurses, social workers, housing officers, employment advisors, Citizens Advice, and even the police can work together to provide a care plan for patients to help prevent health crises.
Engaging with key stakeholders in neighbourhoods
As more care is provided via neighbourhoods, and hospital outpatients’ departments become less important for ongoing long-term condition management, local NHS staffing roles are evolving. However, they are being dictated to a large extent by issues over recruitment, which is the biggest issue facing the NHS.
This means, for example, that in a diabetes super centre, there could be just one diabetes specialist nurse (DSN) supporting a group of practice nurses and pharmacists to manage care. Therefore, some nurses and practice pharmacists may take on wider roles in neighbourhoods and have more responsibility for prescribing.
Indeed, practice pharmacists are becoming increasingly prominent. More than 490 of them were placed in more than 650 practices across England in a pilot project which aimed to have over 2,000 clinical pharmacists working in general practice by 2020/21 – a ratio of one per 30,000 patients, which is equivalent in size to a neighbourhood. Even though the funding is due to end in 2020/21, it is expected that the majority of GP sites involved in NHS England’s clinical pharmacist programme will still continue to employ practice-based pharmacists.
Pharma’s approach
Pharma must take a tailored approach when dovetailing its national market access strategy with neighbourhoods, since each one has unique needs, challenges and priorities. To understand them, pharma sales and key account teams must be familiar with the individual plans of neighbourhoods and keep abreast of the latest developments via sources such as board meeting minutes and operational plans. This type of information can be obtained via digital tools that provide regular email updates.
It is essential that pharma’s own sales and key account teams working in secondary care, primary care and local market access are integrated and that they are thinking holistically across the whole patient pathway as a variety of organisations increasingly work collaboratively with the NHS. In line with this, any value proposition must offer good value to the wider integrated commissioner and provider community as well as the hospital.
Value propositions that demonstrate a reduction in handoffs or clinician time are of particular interest for local integrated care pathways. A classic example of the way in which this can be achieved can be seen in the development of some biosimilar medicines, which are moving away from infusion to subcutaneous injections that can be easily administered by a less specialised workforce and in a community setting.
Services that engage patients in order to help them get the most out of their treatments are likely to play an increasingly important role in keeping them out of hospital and reducing their overall reliance on the NHS in the long-term.
Conclusion
In order to help the NHS deliver integrated care within local communities and reduce costly hospital stays and outpatient attendances, pharma must think holistically across the whole care pathway and ensure that its products meet the needs of the wide variety of stakeholders in the new health and care neighbourhoods.
This requires an in-depth knowledge of the needs and priorities of individual local health economies in tandem with a strategic understanding of where a product fits into the overall care pathway and how it could bring cost savings and improve patient outcomes in the long-run.
Ends
Steve How is a member of Wilmington Healthcare’s Consulting Team. For information on Wilmington Healthcare, log on to www.wilmingtonhealthcare.com
This content was provided by Wilmington Healthcare
Company Details
Latest Content from Wilmington Healthcare
Considering a portfolio review?
Are you considering a portfolio review for your established pharmaceutical brands? Wondering if you should put some activity behind them? At CHASE our experienced team will ensure you maximise your...
UNDERSTANDING THE ROLE OF PLACE WITHIN THE NEW NHS: FIVE THINGS INDUSTRY NEEDS TO KNOW
Operating a level below system, “place” is an increasingly important unit of NHS organisation, yet it remains an evolving concept that is not always well-understood among industry practitioners. In this...
MISSION CRITICAL: HOW PHARMA CAN HELP THE NHS IMPROVE CARE FOR OLDER PEOPLE
With around two-thirds of all hospital beds occupied by over-65s, the care of older patients has long been recognised as key to the sustainability of the NHS. So how is...
ALL CHANGE FOR SPECIALISED COMMISSIONING: FOUR THINGS INDUSTRY NEEDS TO KNOW ABOUT THE LATEST REFORMS
With a recent NHSEI policy document confirming that a major shake-up of arrangements for Specialised Commissioning is imminent, Oli Hudson, Content Director at Wilmington Healthcare (wilmingtonhealthcare.com), describes the key changes...
HOW DID COVID-19 AFFECT PRESCRIBING BEHAVIOURS? FIVE KEY FINDINGS FROM A NEW STATE OF THE NATION REVIEW
Published earlier this month, Wilmington Healthcare’s new State of the Nation report draws on a raft of data from across primary and secondary care to show what actually happened to...
ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
With the Health and Care Act safely passed, Oli Hudson introduces six key stakeholders that will loom large in the new landscape.
Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed
Wilmington Healthcare’s State of the Nation prescribing report shows that spending on sertraline, commonly used to treat depression and anxiety, increased by 305.5% between 2019/20 and 2020/21 while overall spend...
EQUAL FOOTING: HOW PHARMA CAN HELP THE NHS TO ACT ON HEALTH INEQUALITIES
As the NHS puts a renewed focus on reducing health inequalities, Oli Hudson looks at what opportunities this might it bring for Industry and how it can best play its...
UNDERSTANDING THE NEW VALUE PROPOSITION FOR THE NHS
Industry needs a new way of describing its commercial propositions in response to the changing NHS landscape, argues Wilmington Healthcare’s Oli Hudson. This ‘new value proposition’ needs to be reflected...